Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-06-20

Clinical Trial Update: A Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI® [Phase 3]

View source ↗

Summary

Phase 3 trial update comparing Tobrineb, Actitob, and Bramitob with TOBI in cystic fibrosis; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Actitob (tobramycin inhalation solution)
  • Bramitob (tobramycin inhalation solution)
  • TOBI (Tobramycin inhalation solution)
  • Tobrineb (tobramycin inhalation solution)

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Cystic Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2014-06-20